EBIO – Eleven Biotherapeutics, Inc, a clinical-stage biotech company, hit the bottom after announcing that its investigational eye drop failed as a cure for allergic conjunctivitis.

EBIO – Eleven Biotherepeutics, Inc
Fundamentals Previously closed at 0.31
Day’s high 0.31
Day’s low 0.27
P/E ratio NA
EPS -1.71

 

Analyst opinion The recent stock sell-off’s seem to have hit the biotech company really hard, with EBIO hitting a new low, losing more than 90% in value as compared to last year. The failed- experimental eye-drop “isunakinra”, being the biggest reason for the price drop. However, just a week ago, the market cap of EBIO was as low as $5.3 million, which is way low compared to its cash balance reported at the end of Q3 last year which amounts to $46 million
Sentiments Though EPS is negative, we can see that the EPS has improved compared to prior year. EBIO has good fundamentals with a P/S ratio of 7.04, a P/B ratio of 0.20, a P/C ratio of 0.12 and a Quick ratio of 6.20.
91% analysts have a buy opinion for the stock.
Social pulse The social media pulse is 35% lower than normal.

Xactly Corporation is a leading provider of cloud based incentive solutions. It is known for its customer focused business.

XTLY – Xactly Corporation
Fundamentals Previously closed at 4.74
Day’s high 4.87
Day’s low 4.68
P/E ratio NA
EPS -1.99

 

Analysts opinion Xactly announced a new VP Human Resource – Leanne Bernhardt in order to support its expected rapid growth over the next few years. Xactly’s last revenue estimates were higher than analyst expectations.
Sentiments  In comparing the current price level of the equity to their moving averages, the shares are trading -2.09 off of the 50-day average of $7.03 and -3.20 away from the 200-day moving average of $8.14. Now, with many analysts giving a buy rating for the stock, the sentiments have started picking up.
With continued focus on adaptability, and strong fundamentals, xactly is seen as a growth stock and is expected to have good yields for the investors.

Leave a Reply

Your email address will not be published. Required fields are marked *